Evaxion Biotech A/S (EVAX) announced new data underscoring the ability of cancer vaccine EVX-01 to drive a targeted and robust immune response. The data demonstrated that 80% of EVX-01 vaccine targets triggered a tumor-specific immune response. EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma.
The company noted that the phase 2 trial investigated EVX-01 in combination with Merck & Co., Inc.'s anti-PD-1 therapy, KEYTRUDA in patients with advanced melanoma. The trial previously yielded strong interim one-year clinical data and remains on track for readout of two-year clinical data in the second half of 2025.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.